Working on the hypothesis that neurodegeneration is likely to occur during brain tumor evolution, one group analyzed levels of total-Tau (t-Tau) and hyperphosphorylated-Tau(181P) [p-Tau(181P)] in the CSF of 22 children with newly diagnosed brain tumors using monoclonal antibodies (29). The gene discussed is MAPT; the disease is brain neoplasm.